GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » EPS (Basic)

Apollon Formularies (AQSE:APOL) EPS (Basic) : £-0.00 (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies EPS (Basic)?

Apollon Formularies's basic earnings per share (Basic EPS) for the six months ended in Jun. 2023 was £-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.00.

Apollon Formularies's EPS (Diluted) for the six months ended in Jun. 2023 was £-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.00.

Apollon Formularies's EPS without NRI for the six months ended in Jun. 2023 was £-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 47.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Apollon Formularies's highest 3-Year average EPS without NRI Growth Rate was 51.50% per year. The lowest was -63.60% per year. And the median was 22.40% per year.


Apollon Formularies EPS (Basic) Historical Data

The historical data trend for Apollon Formularies's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies EPS (Basic) Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.02 -0.09 - -0.01

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - - -

Apollon Formularies EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Apollon Formularies's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.531-0)/548.103
=-0.00

Apollon Formularies's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.764-0)/771.191
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Apollon Formularies EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 05-22-2015

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

Apollo Group Inc. Reports 10-Q Quarterly Operating Results

By gurufocus gurufocus 06-26-2012